WO2000079267A3 - Use of hte ubiquitin specific protease usp25 in the treatment, prophylaxis and diagnosis of cancer - Google Patents

Use of hte ubiquitin specific protease usp25 in the treatment, prophylaxis and diagnosis of cancer Download PDF

Info

Publication number
WO2000079267A3
WO2000079267A3 PCT/GB2000/002446 GB0002446W WO0079267A3 WO 2000079267 A3 WO2000079267 A3 WO 2000079267A3 GB 0002446 W GB0002446 W GB 0002446W WO 0079267 A3 WO0079267 A3 WO 0079267A3
Authority
WO
WIPO (PCT)
Prior art keywords
usp25
specific protease
ubiquitin
hte
prophylaxis
Prior art date
Application number
PCT/GB2000/002446
Other languages
French (fr)
Other versions
WO2000079267A2 (en
Inventor
Dean Nizetic
Juergen Groet
Original Assignee
Univ London Pharmacy
Dean Nizetic
Juergen Groet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9914589.8A external-priority patent/GB9914589D0/en
Priority claimed from GB0008161A external-priority patent/GB0008161D0/en
Application filed by Univ London Pharmacy, Dean Nizetic, Juergen Groet filed Critical Univ London Pharmacy
Priority to AU55524/00A priority Critical patent/AU5552400A/en
Publication of WO2000079267A2 publication Critical patent/WO2000079267A2/en
Publication of WO2000079267A3 publication Critical patent/WO2000079267A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The product of a gene located at human chromosome 21q11-21 has ubiquitin specific protease activity and binds to ubiquitin, polyubiquitin, ubiquitin-like protein SUMO-3, and proteins which are implicated in the repair/excision of DNA. It is believed to have a role in regulating cell growth, cell growth arrest and/or apoptosis and is implicated in carcinoma growth. The gene has been sequenced and cloned into a microorganism and the product's effect on cell growth is to be investigated. The gene has GenBank accession number AF134213 and has the HUGO-approved name USP25.
PCT/GB2000/002446 1999-06-22 2000-06-22 Use of hte ubiquitin specific protease usp25 in the treatment, prophylaxis and diagnosis of cancer WO2000079267A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55524/00A AU5552400A (en) 1999-06-22 2000-06-22 Treatment of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9914589.8A GB9914589D0 (en) 1999-06-22 1999-06-22 Diagnosis and treatment of alzheimers diease
GB9914589.8 1999-06-22
GB0008161A GB0008161D0 (en) 2000-04-03 2000-04-03 Treatment of cancer
GB0008161.2 2000-04-03

Publications (2)

Publication Number Publication Date
WO2000079267A2 WO2000079267A2 (en) 2000-12-28
WO2000079267A3 true WO2000079267A3 (en) 2001-02-15

Family

ID=26244028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002446 WO2000079267A2 (en) 1999-06-22 2000-06-22 Use of hte ubiquitin specific protease usp25 in the treatment, prophylaxis and diagnosis of cancer

Country Status (2)

Country Link
AU (1) AU5552400A (en)
WO (1) WO2000079267A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709839B1 (en) * 1999-09-24 2004-03-23 Rigel Pharmaceuticals, Inc. SYK-UBP proteins, compositions and methods of use
EP1240335A2 (en) * 1999-12-23 2002-09-18 Incyte Genomics, Inc. Proteases
EP1349922A4 (en) * 2001-01-12 2005-09-07 California Inst Of Techn Regulation of target protein activity through modified proteins
US7122332B2 (en) * 2001-03-29 2006-10-17 Rigel Pharmaceuticals, Inc. Modulators of leukocyte activation, compositions and methods of use
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
EP1771194A2 (en) * 2004-07-07 2007-04-11 Biodevelops Pharma Entwicklung GmbH Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046289A1 (en) * 1998-03-12 1999-09-16 Human Genome Sciences, Inc. 31 human secreted proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046289A1 (en) * 1998-03-12 1999-09-16 Human Genome Sciences, Inc. 31 human secreted proteins

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CAVANI SIMONA ET AL: "Cytogenetic and molecular study of 32 Down syndrome families: Potential leukaemia predisposing role of the most proximal segment of chromosome 21q.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 103, no. 1, October 1998 (1998-10-01), pages 213 - 216, XP000943387, ISSN: 0007-1048 *
DATABASE EMBL 24 June 1997 (1997-06-24), STRAUSBERG, R.: "Homo sapiens cDNA clone IMAGE:824710 5' similar to SW:UBP2-YEAST Q01476 UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 2", XP002152574 *
DATABASE EMBL 29 November 1996 (1996-11-29), HILLIER, L. ET AL.: "Homo sapiens cDNA clone IMAGE:549350 5' similar to WP:K02C4.3 CE01599 UBIQUITIN CARBOXYL-TERMINAL HYDROLASE", XP002152573 *
FUJIWARA TSUTOMU ET AL: "Identification and chromosomal assignment of USP1, a novel gene encoding a human ubiquitin-specific protease.", GENOMICS, vol. 54, no. 1, 15 November 1998 (1998-11-15), pages 155 - 158, XP002153254, ISSN: 0888-7543 *
GROET JUERGEN ET AL: "Bacteria contig map of the 21q11 region associated with Alzheimer's disease and abnormal myelopoiesis in Down syndrome.", GENOME RESEARCH, vol. 8, no. 4, April 1998 (1998-04-01), pages 385 - 398, XP002152570, ISSN: 1088-9051 *
GROET JURGEN ET AL: "Narrowing of the region of allelic loss in 21q11-21 in squamous non-small cell lung carcinoma and cloning of a novel ubiquitin-specific protease gene from the deleted segment.", GENES CHROMOSOMES & CANCER, vol. 27, no. 2, February 2000 (2000-02-01), pages 153 - 161, XP000943091, ISSN: 1045-2257 *
HILLIER, L. ET AL.: "Generation and analysis of 280,000 human expressed sequence tags", GENOME RES., vol. 6, no. 9, 1996, pages 807 - 828, XP002922485 *
KOHNO TAKASHI ET AL: "Homozygous deletion and frequent allelic loss of the 21q11.1-q21.1 region including the ANA gene in human lung carcinoma.", GENES CHROMOSOMES & CANCER, vol. 21, no. 3, March 1998 (1998-03-01), pages 236 - 243, XP000943071, ISSN: 1045-2257 *
VALERO REBECA ET AL: "USP25, a novel gene encoding a deubiquitinating enzyme, is located in the gene-poor region 21q11.2.", GENOMICS, vol. 62, no. 3, 15 December 1999 (1999-12-15), pages 395 - 405, XP002152572, ISSN: 0888-7543 *
WILKINSON KEITH D: "Regulation of ubiquitin-dependent processes by deubiquitinating enzymes.", FASEB JOURNAL, vol. 11, no. 14, December 1997 (1997-12-01), pages 1245 - 1256, XP000943130, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
AU5552400A (en) 2001-01-09
WO2000079267A2 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
Zimmerman et al. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. Implications for mechanisms of action.
Overall et al. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression
Kjeldsen et al. Sequence-dependent effect of camptothecin on human topoisomerase I DNA cleavage
HK1047129A1 (en) Sequence-specific dna recombination in eukaryotic cells
DE69922484D1 (en) ANTI-KRYPTOKOKKUS PEPTIDE
IN2014DN02483A (en)
WO2002044736A3 (en) Diagnosis and treatment of epidermal or skin diseases
WO2000079267A3 (en) Use of hte ubiquitin specific protease usp25 in the treatment, prophylaxis and diagnosis of cancer
WO1999015643A3 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
Saraste et al. A gene in Paracoccus for subunit III of cytochrome oxidase
Schechter et al. Determination of the primary structures of human skin chymase and cathepsin G from cutaneous mast cells of urticaria pigmentosa lesions.
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
WO2002008392A3 (en) Regulation of human matriptase-like serine protease
WO2000078934A3 (en) Use of the ubiquitin specific protease usp25 in the diagnosis and treatment of alzheimer's disease
Gu et al. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines
EP0785214A3 (en) Amylase inhibitors
AU6218690A (en) Rna with endoribonuclease activity for mrna of ripening genes, the preparation thereof and the use thereof in plants
Menz et al. Matrix NADH dehydrogenases of plant mitochondria and sites of quinone reduction by complex I
WO2004076690A3 (en) Use of a mutation in the human gnas gene for predicting risks of disease, courses of diseases, and for predicting the response to treatments of disease
WO2005049818A3 (en) Genes encoding human deubiquitinating enzymes
WO2002000878A3 (en) Human msp1 mitochondrial dynamin, its msp1-x isoforms, and their therapeutic use
WO2003066808A3 (en) Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
WO1999045116A3 (en) Human homolog of a nuclear migration gene and its use
Goldfarb Role of neutral serine proteases in tumor cell lysis by natural killer cells (large granular lymphocytes) and activated macrophages
Mogulevtseva et al. Impact of Metalloproteinase 1 Deficiency Induced by Specific Small Hairpin RNA on the Physiological Effects of Tumor Necrosis Factor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP